Boston Scientific sales buoyed by 219% Taxus growth:
This article was originally published in Clinica
Boston Scientific's sales rose by 49% to $1.6bn in the first quarter, as its Taxus drug-eluting stent generated growth of 219% to $686m. Sales of the device were $494m in the US, where it was launched in March 2004. The company's net income rose by 85% to $358m. "In the coming quarters, we expect our recent dramatic growth to return to more moderate levels, following a full year of Taxus system sales in the US", said president and CEO Jim Tobin. The company holds some 60% or more of the US DES market, with Johnson & Johnson its only commercial competitor to date (see page 13).